Revenue - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Revenue			$ 8,766,000
License And Service [Member]
Disaggregation Of Revenue [Line Items]
Revenue			8,766,000
Neurocrine Biosciences [Member] | License And Service [Member]
Disaggregation Of Revenue [Line Items]
Research and development services			1,270,000
Milestone payments			$ 7,124,000
License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member]
Disaggregation Of Revenue [Line Items]
Upfront payment received in cash				$ 30,000,000
Upfront payment received in equity investment				20,000,000
Equity investment measured at fair value				16,667,000
Collaborate agreement premium related to equity investment				3,333,000
Transaction price allocated to performance obligations				$ 33,333,000
Milestone Payment Received	$ 15,000,000
Milestone Payment Received in Cash	6,750,000
Milestone Payment Received in Equity Investment	8,250,000
Equity investment measure at fair value	7,876,000
Premium	374,000
Performance obligation related to milestone	0
Revenue	$ 6,750,000
Potential milestone payments receivable		$ 1,667,500,000
Percentage of option to co-fund development costs upon achievement of certain milestones		50.00%
License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member] | Regulatory Milestone [Member]
Disaggregation Of Revenue [Line Items]
Potential milestone payments receivable		$ 1,067,500,000
License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member] | Sales Based Milestone [Member]
Disaggregation Of Revenue [Line Items]
Potential milestone payments receivable		$ 600,000,000